Vision loss, diabetic macular edema and diabetic retinopathy are complications of diabetes mellitus that occur in roughly one third of patients 10 years after the onset of diabetes. Optina™ is an oral drug with an established human safety profile. Pre-clinical studies have shown the potential for Optina™ to significantly reduce diabetic macular edema in patients. Ampio Pharmaceuticals has completed a formal agreement with St Michael's Hospital, Toronto, Canada as a final step for ethics board approval, which is expected in the next few days.